A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.

导出 LinkOut

翻译打印收藏纠错

第一作者： Arthur A,Simen

第一单位： Merck Research Laboratories, Merck Sharp & Dohme, North Wales, PA 19454, USA. Present address: Pfizer Worldwide Research & Development, Cambridge, MA 02139, USA.

作者： Arthur A,Simen ^[1] ; Cynthia,Gargano ^[2] ; Jang-Ho,Cha ^[3] ; Melissa,Drexel ^[3] ; An,Bautmans ^[4] ; Ingeborg,Heirman ^[4] ; Tine,Laethem ^[4] ; Thomas,Hochadel ^[5] ; Lien,Gheyle ^[6] ; Kim,Bleys ^[6] ; Chan,Beals ^[3] ; Aubrey,Stoch ^[3] ; Gary G,Kay ^[5] ; Arie,Struyk ^[3]

作者单位： Merck Research Laboratories, Merck Sharp & Dohme, North Wales, PA 19454, USA. Present address: Pfizer Worldwide Research & Development, Cambridge, MA 02139, USA. ^[1] Johnson & Johnson, Springhouse, PA 19477. ^[2] Merck Research Laboratories, Merck Sharp & Dohme, North Wales, PA, USA. ^[3] Merck ESD EU, MSD Europe Inc., Belgium. ^[4] Cognitive Research Corporation, Saint Petersburg, FL, USA. ^[5] SGS Life Science Services, Antwerp, Belgium. ^[6]

关键词 cognition driving simulation hypnotics next-day residual drug effects standard deviation of lane position

DOI 10.1177/2042098615579314

PMID 26240742

发布时间 2020-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览148

Therapeutic advances in drug safety

2015年6卷3期

86-97页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.

Therapeutic advances in drug safety

相似文献

Therapeutic advances in drug safety

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.

Therapeutic advances in drug safety

相似文献

Therapeutic advances in drug safety

相关期刊

检索历史清除